"Leuprolide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE that regulates the synthesis and release of pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE.
| Descriptor ID |
D016729
|
| MeSH Number(s) |
D06.472.699.327.740.320.400 D12.644.400.400.740.320.400 D12.644.456.460.480 D12.644.548.365.740.320.400 D12.776.631.650.405.740.320.400
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Leuprolide".
Below are MeSH descriptors whose meaning is more specific than "Leuprolide".
This graph shows the total number of publications written about "Leuprolide" by people in this website by year, and whether "Leuprolide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 2 | 1 | 3 |
| 2007 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Leuprolide" by people in Profiles.
-
Wallach JD, Deng Y, McCoy RG, Dhruva SS, Herrin J, Berkowitz A, Polley EC, Quinto K, Gandotra C, Crown W, Noseworthy P, Yao X, Shah ND, Ross JS, Lyon TD. Real-world Cardiovascular Outcomes Associated With Degarelix vs Leuprolide for Prostate Cancer Treatment. JAMA Netw Open. 2021 10 01; 4(10):e2130587.
-
Bowen RL, Perry G, Xiong C, Smith MA, Atwood CS. A clinical study of lupron depot in the treatment of women with Alzheimer's disease: preservation of cognitive function in patients taking an acetylcholinesterase inhibitor and treated with high dose lupron over 48 weeks. J Alzheimers Dis. 2015; 44(2):549-60.
-
Palmer CB, Forstein DA, Higdon HL, Boone WR. Changes in long luteal protocol affects the number of days of stimulation: evolution of an assisted reproductive technology practice. J Reprod Med. 2011 Jul-Aug; 56(7-8):308-12.
-
Webber KM, Perry G, Smith MA, Casadesus G. The contribution of luteinizing hormone to Alzheimer disease pathogenesis. Clin Med Res. 2007 Oct; 5(3):177-83.
-
Bhasin S, Woodhouse L, Casaburi R, Singh AB, Mac RP, Lee M, Yarasheski KE, Sinha-Hikim I, Dzekov C, Dzekov J, Magliano L, Storer TW. Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J Clin Endocrinol Metab. 2005 Feb; 90(2):678-88.
-
Casadesus G, Zhu X, Atwood CS, Webber KM, Perry G, Bowen RL, Smith MA. Beyond estrogen: targeting gonadotropin hormones in the treatment of Alzheimer's disease. Curr Drug Targets CNS Neurol Disord. 2004 Aug; 3(4):281-5.
-
Bowen RL, Verdile G, Liu T, Parlow AF, Perry G, Smith MA, Martins RN, Atwood CS. Luteinizing hormone, a reproductive regulator that modulates the processing of amyloid-beta precursor protein and amyloid-beta deposition. J Biol Chem. 2004 May 07; 279(19):20539-45.